Business Card for Diane Gardner:


Director, Database Ops
New York City, NY area
Email Avail: 3 Day Free Trial


86 Morris Ave
Summit, NJ 07901

Tel: (908) 673-9000

Last updated on 2017-04-02


About Diane Gardner:

Diane Gardner works as an Director, Database Ops for Celgene at New York City, NY. The company's webpage is http://www.celgene.com. For email, phone number and executive profiles for Director, Database Ops and other executives of Celgene at New York City, NY, check Celgene at Joesdata.com. Not the Diane Gardner you are looking for? Do a quick search in our website and find other people named Diane Gardner.
Diane Gardner's Work History:
No information available..

Diane Gardner's Education:
No information available..

Diane Gardner's Co-workers:
As of January 25, 2020, Diane Gardner has 953 co-workers under the company name Celgene at Joesdata.com.

About Celgene:


Warning: mysqli_fetch_assoc() expects parameter 1 to be mysqli_result, boolean given in /home2/joesdata/public_html/login/executivedetails.php on line 392
Celgene is located at 86 Morris Ave , Summit, NJ 07901. It has over 10K employees. Its revenue is over $1B.

Company News:
2018-09-12 17:30:52
OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
2018-07-10 19:24:21
Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
2018-07-10 17:30:42
Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
2018-06-03 18:54:37
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
2018-06-03 17:31:02
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
2018-06-01 18:54:20
Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
2018-06-01 17:30:39
Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
2018-05-22 18:54:17
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018
2018-05-22 17:30:52
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018
2018-05-16 18:54:19
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions

People in the same industry: